T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells.

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...